KOL kliniske forsøg i Tennessee
14 studier for KOL søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
- Research Site, Tullahoma
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Chattanooga Research and Medicine- Site Number : 8400026, Chattanooga
- Premier Research Center, Llc- Site Number : 8400146, Hendersonville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 1. okt. 2026 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Meharry Medical College- Site Number : 8400133, Nashville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07190209An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- Fort Sanders Regional Medical Center (StatCare), Knoxville
Rekrutterer
Alder 40 til 80 · Alle køn · Opdateret 17. sep. 2026 · NCT06035120A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Knoxville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Franklin
- Research Site, Johnson City
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Clinical Trials Center of Middle Tennessee, LLC, Franklin
- Premier Research Center, LLC, Hendersonville
RekruttererFase 2/3
Alder 35 til 80 · Alle køn · Opdateret 31. aug. 2026 · NCT07363694Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
- The University of Tennessee Graduate School of Medicine, Knoxville
RekruttererFase 4
Alder 40 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07133880eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Knoxville
RekruttererFase 3
Alder 40 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07177339Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Methodist LeBonheur Healthcare, Memphis
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05181826Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Knoxville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 9. apr. 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- The Jackson Clinic, PA, Jackson
RekruttererObservationsstudie
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2025 · NCT06122077Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.